AstraZeneca DTP Rx Deal With Trump Follows Pfizer Model

By Maaisha Osman / October 10, 2025 at 7:34 PM

AstraZeneca became the second drugmaker to partner with the Trump administration to sell chronic disease medications directly to patients at discounts of up to 80% through the TrumpRx website, while also securing a three-year exemption from Section 232 tariffs in exchange for onshoring its U.S. manufacturing.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.